# A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

> **NCT00985959** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 101 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** JNJ-26866138 0.7 mg/m2
- **DRUG:** JNJ-26866138 1.0 mg/m2
- **DRUG:** JNJ-26866138 1.3 mg/m2
- **DRUG:** Melphalan
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT00985959
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2013-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00985959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00985959, "A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00985959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*